If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
164
results.
Updated on
16/02/2026 [07:24:00]
Results 50 to 75 of 164
Absstract of: US20260027178A1
The present disclosure generally relates to the treatment of subjects having Parkinson's disease or at risk of developing Parkinson's disease by administering a SIM BHLH Transcription Factor 2 (SIM2) agonist to the subject.
Absstract of: US20260027179A1
Disclosed is a method of treating a neurodegenerative disease such as Parkinson's disease, diffuse Lewy body disease, transitional Lewy body dementia, and multiple system atrophy in a subject. The method comprises administering to the subject a therapeutically effective amount of a peptide comprising an α-synuclein binding domain operably linked to a protein transduction domain and a proteasomal targeting domain, wherein the α-synuclein binding domain is derived from a reversed sequence of β-synuclein. Other methods, as well as uses and compositions, are disclosed.
Absstract of: US20260027157A1
Methods to alleviate or treat Alzheimer's Disease or a neurological disorder or disorder, or to alleviate the symptoms of each thereof are provided, the methods comprising administering an effective amount of (HSPC) or a population of HSPCs to the subject, that are optionally gene-corrected prior to administration and that will differentiate on healthy microglia cells in the brain. The cells are capable of decreasing amyloid plaques and inflammation.
Absstract of: AU2025205167A1
A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease. A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.20 ul u l
Absstract of: AU2025205168A1
An anti-DAT antibody which is formed from a gene comprising SEQ ID No:2 after transcription and translation. The anti-DAT antibody of the present invention can be made into a composition capable of crossing the blood-brain barrier, and specifically binding to dopamine nerve cells, and achieving excellent efficacy in reducing the accumulation of α- syn in the striatum and delaying the course of Parkinson's disease. An anti-DAT antibody which is formed from a gene comprising SEQ ID No:2 after transcription and translation. The anti-DAT antibody of the present invention can be made into a composition capable of crossing the blood-brain barrier, and specifically binding to dopamine nerve cells, and achieving excellent efficacy in reducing the accumulation of - syn in the striatum and delaying the course of Parkinson's disease. ul u l
Absstract of: AU2024288766A1
The invention relates to liposome-encapsulated apomorphine, processes for preparing said liposome-encapsulated apomorphine and to the use of such in the treatment of Parkinson's disease.
Absstract of: WO2026022191A1
The present invention relates to the field of neurodegenerative diseases, in particular Alzheimer's disease. The present invention further relates to fibrillary Apolipoprotein E (ApoE) for use in a method of treatment and/or prevention of a neurodegenerative disease and methods of producing said fibrillary ApoE. Moreover, the present invention relates to an antigen-binding peptide specifically binding to fibrillary ApoE, preferably human ApoE, a method of generating said antigen-binding peptide, and its use in a method of treatment and/or prevention and/or diagnosis of a neurodegenerative disease in a patient in need thereof.
Absstract of: WO2026025015A1
The present disclosure generally relates to the treatment of subjects having Parkinson's disease or at risk of developing Parkinson's disease by administering a SIM BHLH Transcription Factor 2 (SIM2) agonist to the subject.
Absstract of: EP4685158A1
The present invention relates to the field of neurodegenerative diseases, in particular Alzheimer's disease. The present invention further relates to fibrillary Apolipoprotein E (ApoE) for use in a method of treatment and/or prevention of a neurodegenerative disease and methods of producing said fibrillary ApoE. Moreover, the present invention relates to an antigen-binding peptide specifically binding to fibrillary ApoE, preferably human ApoE, a method of generating said antigen-binding peptide, and its use in a method of treatment and/or prevention and/or diagnosis of a neurodegenerative disease in a patient in need thereof.
Absstract of: AU2024238511A1
The present disclosure relates to biomarkers and uses thereof in methods for selecting a patient diagnosed with amyotrophic lateral sclerosis (ALS) for an ALS therapy. The present disclosure further relates to methods for identifying the severity of ALS in a patient, treating an ALS patient, and monitoring efficacy of an ALS treatment.
Absstract of: AU2024307361A1
Described herein are crystalline forms of 6-(6-(((1R,2R,3S,5S)-2-fluoro-9-azabicyclo3.3.1nonan-3-yl)(methyl)amino)pyridazin-3-yl)-2-methylbenzodoxazol-5-ol (compound A), a small molecule splicing modulator (SMSM) of mRNA, such as pre-mRNA, encoded by genes, for the treatment of Huntington's disease.
Absstract of: US20260022376A1
The present disclosure provides novel approaches to the treatment of Alzheimer's disease, and other neurodegenerative disorders such as chronic traumatic encephalopathy (CTE) using novel therapeutics comprising agents that reduce the interaction of a tau seed interactor with intracellular tau proteins and thus reduce or inhibit the production of tau-associated neurofibrillary tangles.
Absstract of: WO2026018015A2
The present invention relates inter alia to methods for identifying a substance useful for the prevention or treatment of a disease, disorder, or condition associated with altered NLRX1 activity, and uses of said substances in the prevention or treatment of a disease, disorder, or condition associated with altered NLRX1 activity, for example in the prevention or treatment of Parkinson's disease or amyotrophic lateral sclerosis.
Absstract of: WO2026019879A1
The general field of the present disclosure are novel approaches to the treatment of Alzheimer's and other neurodegenerative disorders using novel therapeutics comprising Lyn kinase inhibitors. Specifically, the disclosure provides compounds, pharmaceutical compositions, and methods of treating and preventing such disorders.
Absstract of: WO2026020153A1
Composition and methods for treating neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Angelman's Syndrome (AS), the compositions specifically including antisense oligonucleotides (ASOs) containing thiomorpholino nucleotides configured to inhibit ribosomal frameshifting of paternally expressed gene 10 (PEG 10) mRNA during translation, thereby inhibiting the formation of the long form gag-pol protein.
Absstract of: WO2026020097A1
Provided herein are postbiotic compositions prepared using successive fermentation methods of specific bacteria and plant fiber material. Also provided herein are methods, including for the treatment or prevention of the disruption of gut microbiota, or dysbiosis, associated with an antibiotic treatment, chemotherapy treatment, or administration of a dysbiosis-causing medications or medical treatments, using said postbiotic compositions, or for improving responses and/or reducing complications to treatments such as antibiotics or chemotherapy. Such postbiotic compositions can also be used for the treatment or prevention of the disruption of the gut-brain axis, including to treat or prevent neurological diseases or disorders, such as synucleinopathies, including but not limited to Parkinson's disease.
Absstract of: WO2026019699A1
The present disclosure is directed to engineered cells designed to sense tau and to express one or more proteins in response to this binding event. In addition, the cells and associated methods of use can detect, treat, and recapitulate the symptoms of Alzheimer's disease. The engineered cells can regulate expression of neuronal growth factors and anti-inflammatory proteins to address neurodegeneration and neuroinflammation, respectively.
Absstract of: WO2026018824A1
The purpose of the present invention is to provide a drug for treating or preventing neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The present inventors identified oligonucleotides that inhibit MP-13 mRNA, which is a splicing variant (TDPsv) of TDP-43. Use of these oligonucleotides can reduce the amount of MP-13 mRNA and suppress protein expression. These oligonucleotides can be useful for the treatment or prevention of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).
Absstract of: WO2026018132A1
Provided is a method for treating a condition selected from the group consisting of pain, sleep disorder, cancer, Alzheimer's disease, neurodegenerative diseases, ulcer, hypertension, opioid- related adverse effects, inflammation, asthma, glaucoma, neurodevelopment diseases and combinations thereof in a subject in need thereof, the method comprising administering to the subject: a) a first active pharmaceutical ingredient (API) comprising at least one cannabinoid other than CBD and THC; and b) a second API, which is different from the first API.
Absstract of: WO2026017171A1
The present invention relates to a heterocyclic carbonyl derivative modulator, a preparation method therefor and a use thereof. In particular, the present invention relates to a compound represented by general formula (VIII-1A), a preparation method therefor, a pharmaceutical composition containing the compound, and a use of the compound as a modulator in the treatment of Alzheimer's disease, schizophrenia, pain, addiction, and sleep disorders. Each substituent in general formula (VIII-1A) is the same as defined in the description.
Absstract of: WO2026017114A1
Use of a phenylpyrimidinone compound. The present invention specifically relates to use of a phenylpyrimidinone compound represented by formula (I) or a tautomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or an isotopically labelled compound thereof in the preparation of a drug for ameliorating or treating cognitive impairment, and/or ameliorating or treating cerebrovascular diseases. Studies using cell and animal models have shown that compared to the commercially available clinical drug donepezil and the investigational clinical drug mirodenafil, the compound has demonstrated significant therapeutic characteristics and substantial technical advancements in terms of protecting nerve cells, ameliorating cognitive impairment, ameliorating cerebrovascular diseases, and ameliorating degenerative diseases such as Parkinson's disease.
Absstract of: WO2026016523A1
The use of the traditional Chinese medicine (TCM) components to manufacture the medicament for diminishing effects of Amyotrophic Lateral Sclerosis (ALS) or neurodegeneration in a predisposed subject, wherein the TCM comprising: (1) Ge Gen, (2) Dang Gui, (3) Dan Shen, (4) Dang Shen, (5) Huang Qi, (6) Zi Su Zi, (7) Da Zao, (8) Chai Hu, (9) Huang Qin, (10) Hong Hua, (l l) Yu Jin, (12) Da Huang, (13) Hua Jiao, (l4) Gan Cao, (15) Mai Dong, (l6) Wu Wei Zi, (17) Fu Zi, (18) Ren Shen, (l9) Fu Ling, (20) Shi Gao, (21) Mu Li, (22) Gui Zhi, and (23) Che Qian Zi; or, extracts thereof in amounts equivalent to the amounts of the raw materials of the group of ingredients. The patent is targeted on the clinical efficacy of the different pathological forms of ALS disease manifestation. The medicament could be used in a combination with a Western medicine.
Absstract of: WO2026016262A1
Provided is use of cobra neurotoxin and a formulation thereof in the preparation of a drug for preventing and/or treating Alzheimer's disease. The cobra neurotoxin is selected from Chinese cobrotoxin and/or Thai cobratoxin. The formulation of the cobra neurotoxin is selected from Cobratide, Cobratide injection, Nyloxin, cobraxin, peperon, or at least one of clinically acceptable non-injection dosage forms prepared from the described formulations. Intranasal administration of Cobratide has a good effect in treating Alzheimer's disease. Meanwhile, no significant toxic and side effects are found in the therapeutic dose, and Cobratide has the advantages of a small dosage and safety.
Absstract of: AU2024281419A1
The present invention relates to a pharmaceutical composition comprising crisdesalazine or a salt thereof, which has improved stability by reducing the content of related substances of crisdesalazine, and has an increased dissolution rate by improving the intrinsic solubility thereof. The composition of the present invention secures stability and bioavailability, and thus is more effective in treating neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, epilepsy accompanied by free radical neurotoxicity, cerebral trauma, spinal injury, and the like), inflammatory diseases (gastritis, colitis, pancreatitis, arthritis, diabetic inflammation, inflammatory bowel disease, nephritis, hepatitis, arteriosclerosis inflammation, and the like), stress disorders (anxiety disorder, depression, and the like), and the like.
Nº publicación: US20260021150A1 22/01/2026
Applicant:
INTEGRATED MOLECULAR MEDICINE LTD [HK]
Integrated Molecular Medicine Limited
Absstract of: US20260021150A1
Disclosed is a method for diminishing effects of Amyotrophic Lateral Sclerosis (ALS) in administering to the predisposed subject effective amounts of Traditional Chinese Medicine (TCM) or in a combination of a Western medicine, wherein the TCM including: (1) Ge Gen, (2) Dang Gui, (3) Dan Shen, (4) Dang Shen, (5) Huang Qi, (6) Zi Su Zi, (7) Da Zao, (8) Chai Hu, (9) Huang Qin, (10) Hong Hua, (I I) Yu Jin, (12) Da Huang, (13) Hua Jiao, (I4) Gan Cao, (15) Mai Dong, (I6) Wu Wei Zi, (17) Fu Zi, (18) Ren Shen, (I9) Fu Ling, (20) Shi Gao, (21) Mu Li, (22) Gui Zhi, and (23) Che Qian Zi; or, extracts thereof in amounts equivalent to the amounts of the raw materials of the group of ingredients. The patent is targeted on the clinical efficacy of the different pathological forms of ALS disease manifestation.
BOPI
Electronic site
